Carlos Fernandez-Patron

Dr. Carlos Fernandez-Patron

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2004 in Circulation Research
Verified
Journal Article
Closed access
PDF file
LHLi Hao
Li Hao
MDMin Du
Min Du
ALAna Lopez-Campistrous
Ana Lopez-Campistrous
CFCarlos Fernandez-Patron
Carlos Fernandez-Patron
Matrix metalloproteinase (MMP)-dependent shedding of heparin-binding epidermal growth factor (HB-EGF) and subsequent activation of the EGF receptor (EGFR) in the cardiovasculature is emerging as a unique mechanism signaling growth effects of diverse G protein–coupled receptors (GPCRs). Among these GPCRs are adrenoceptors and angiotensin receptors that contribute to the pathogenesis of hypertension through their vasoconstrictive and growth effects. Focusing on α 1b -adrenoceptors, we suggest here that MMP-dependent activation of the EGFR promotes vasoconstriction as well as growth. We identified MMP-7 as a major HB-EGF sheddase in rat mesenteric arteries and α 1b -adrenoceptors, angiotensin receptors, and hypertension-stimulated MMP-7 activity. Adrenoceptors stimulated EGFR autophosphorylation in arteries, and this transactivation was opposed by the MMP-7 inhibitor GM6001 as well as MMP-7–specific antibodies. In isolated microperfused arteries, blockade of EGFR transactivation with inhibitors of the EGFR (AG1478 and PD153035), HB-EGF (CRM197 and neutralizing antibodies), or MMPs (doxycycline) inhibited adrenergic vasoconstriction. In spontaneously hypertensive rats but not in normotensive rats, the inhibition of MMPs with doxycycline (19.2 mg/d from week 7 until week 12) reduced systolic blood pressure and attenuated HB-EGF shedding in the mesenteric arteries. These findings suggest a previously unknown mechanism of vasoregulation whereby agonists of certain GPCRs (such as adrenoceptors and angiotensin receptors) activate MMPs (such as MMP-7) that shed EGFR ligands (such as HB-EGF), which then activate the EGFR, thereby promoting vasoconstriction as well as growth. Because this mechanism is triggered by agonists typically overexpressed in hypertension, its blockade may have therapeutic potential for simultaneously inhibiting pathological vasoconstriction and growth in hypertensive disorders.

13 October 2000 in Circulation Research
Verified
Journal Article
Open access
PDF file
CFCarlos Fernandez-Patron
Carlos Fernandez-Patron
KSKen G. Stewart
Ken G. Stewart
YZYunlong Zhang
Yunlong Zhang
EKErkki Koivunen
Erkki Koivunen
MRMarek W. Radomski
Marek W. Radomski
Sandra T DavidgeSandra T Davidge
Sandra T Davidge
—Matrix metalloproteinase (MMP)-2 has been historically associated with the process of vascular remodeling through the cleavage of extracellular matrix proteins. However, we recently found that MMP-2 also cleaves the endothelium-derived peptide big endothelin-1, ET-1[1–38] and yields the novel vasoconstrictor ET-1[1–32]. We therefore investigated the effects of MMP-2 inhibitors as potential vasodilators. MMP inhibition with ortho-phenanthroline (0.3 to 30 μmol/L) induced vasorelaxation of isolated rat mesenteric arteries (maximum of relaxation=74.5±27.6% at 30 μmol/L). However, phosphoramidon (0.3 to 30 μmol/L), which inhibits some metalloenzymes, but not MMP-2, did not dilate the arteries. Selective inhibition of endogenous MMP-2 with the novel tissue-permeable cyclic peptide CTTHWGFTLC (CTT, 10 μmol/L) also caused vasorelaxation (by 85±6%), whereas STTHWGFTLS (10 μmol/L), an inactive CTT analogue, did not dilate the arteries. Interestingly, the vasorelaxation that results from MMP-2 inhibition was endothelium-independent. Thus, we examined whether MMP-2 acted on peptides derived from the smooth muscle or the perivascular nerves. Recombinant human MMP-2 cleaved calcitonin gene-related peptide (CGRP) specifically at the Gly14-Leu15peptide bond and reduced the vasodilatory potency of CGRP by 20-fold. Inhibition of MMP-2 increased the amount of intact CGRP in arteries and enhanced vasorelaxation induced by anandamide, which stimulates CGRP release. Vasorelaxation in response to MMP-2 inhibition was abolished by CGRP[8–37], a selective CGRP receptor antagonist, and by capsaicin, which depletes arterial perivascular nerves of CGRP. We conclude that vascular MMP-2 cleaves endogenous CGRP and promotes vasoconstriction. These data suggest a novel mechanism of regulating the vasoactive and, possibly, the neurohormonal actions of CGRP and establish MMP-2 as a modulator of vascular function.

5 February 2020 in Frontiers in Physiology
Verified
Journal Article
Open access
EHEugenio Hardy
Eugenio Hardy
CFCarlos Fernandez-Patron
Carlos Fernandez-Patron
Bone is a dynamic organ that undergoes constant remodeling, an energetically costly process by which old bone is replaced and localized bone defects are repaired to renew the skeleton over time, thereby maintaining skeletal health. This review provides a general overview of bone’s main players (bone lining cells, osteocytes, osteoclasts, reversal cells, and osteoblasts) that participate in bone remodeling. Placing emphasis on the family of extracellular matrix metalloproteinases (MMPs), we describe how: (i) Convergence of multiple protease families (including MMPs and cysteine proteinases) ensures complexity and robustness of the bone remodeling process, (ii) Enzymatic activity of MMPs affects bone physiology at the molecular and cellular levels and (iii) Either overexpression or deficiency/insufficiency of individual MMPs impairs healthy bone remodeling and systemic metabolism. Today, it is generally accepted that proteolytic activity is required for the degradation of bone tissue in osteoarthritis and osteoporosis. However, it is increasingly evident that inactivating mutations in MMP genes can also lead to bone pathology including osteolysis and metabolic abnormalities such as delayed growth. We argue that there remains a need to rethink the role played by proteases in bone physiology and pathology.

1 November 2018 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
EHEugenio Hardy
Eugenio Hardy
AHAnette Hardy-Sossa
Anette Hardy-Sossa
CFCarlos Fernandez-Patron
Carlos Fernandez-Patron
Matrix metalloproteinase (MMP)-2 cleaves a broad spectrum of substrates, including extracellular matrix components (responsible for normal tissue remodeling) and cytokines (modulators of the inflammatory response to physiological insults such as tissue damage). MMP-2 expression is elevated in many cardiovascular pathologies (e.g., myocardial infarction, hypertensive heart disease) where tissue remodeling and inflammatory responses are perturbed. Thus, it has generally been assumed that blockade of MMP-2 activity will yield therapeutic effects. Here, we provide a counterargument to this dogma based on 1) preclinical studies on Mmp2-null ( Mmp2−/−) mice and 2) clinical studies on patients with inactivating MMP2 gene mutations. Furthermore, we put forward the hypothesis that, when MMP-2 activity falls below baseline, the bioavailability of proinflammatory cytokines normally cleaved and inactivated by MMP-2 increases, leading to the production of cytokines and cardiac secretion of phospholipase A2activity into the circulation, which stimulate systemic inflammation that perturbs lipid metabolism in target organs. Finally, we suggest that insufficient understanding of the consequences of MMP-2 deficiency remains a major factor in the failure of MMP-2 inhibitor-based therapeutic approaches. This paucity of knowledge precludes our ability to effectively intervene in cardiovascular and noncardiovascular pathologies at the level of MMP-2.

29 October 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SHSamuel Hernandez‐Anzaldo
Samuel Hernandez‐Anzaldo
EBEvan Berry
Evan Berry
VBVesna Brglez
Vesna Brglez
DLDickson Leung
Dickson Leung
TYTae Jin Yun
Tae Jin Yun
CFCarlos Fernandez-Patron
Carlos Fernandez-Patron
Background: Endocrine functions of the heart have been well established. We investigated the hypothesis that cardiac secretion of a unique phospholipase A 2 recently identified by our laboratory (cardiac secreted phospholipase A 2 [ sPLA 2 ]) establishes a heart–liver endocrine axis that is negatively regulated by matrix metalloproteinase‐2 (MMP‐2). Methods and Results: In Mmp2 −/− mice, cardiac (but not hepatic) sPLA 2 was elevated, leading to hepatic inflammation, immune cell infiltration, dysregulation of the sterol regulatory element binding protein‐2 and liver X receptor‐α pathways, abnormal transcriptional responses to dietary cholesterol, and elevated triglycerides in very low‐density lipoprotein and in the liver. Expression of monocyte chemoattractant protein‐3, a known MMP‐2 substrate, was elevated at both mRNA and protein levels in the heart. Functional studies including in vivo antibody neutralization identified cardiac monocyte chemoattractant protein 3 as a possible agonist of cardiac sPLA 2 secretion. Conversely, systemic sPLA 2 inhibition almost fully normalized the cardiohepatic phenotype without affecting monocyte chemoattractant protein‐3. Finally, wild‐type mice that received h igh‐performance liquid chromatography –isolated cardiac sPLA 2 from Mmp2 −/− donors developed a cardiohepatic gene expression profile similar to that of Mmp2 −/− mice. Conclusions: These findings identified the novel MMP‐2/cardiac sPLA 2 pathway that endows the heart with important endocrine functions, including regulation of inflammation and lipid metabolism in the liver. Our findings could also help explain how MMP 2 deficiency leads to cardiac problems, inflammation, and metabolic dysregulation in patients.

22 April 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EBEvan Berry
Evan Berry
SHSamuel Hernandez‐Anzaldo
Samuel Hernandez‐Anzaldo
FGFarideh Ghomashchi
Farideh Ghomashchi
RLRichard Lehner
Richard Lehner
MMMakoto Murakami
Makoto Murakami
CFCarlos Fernandez-Patron
Carlos Fernandez-Patron
Background: Matrix metalloproteinase ( MMP )‐2 deficiency makes humans and mice susceptible to inflammation. Here, we reveal an MMP ‐2–mediated mechanism that modulates the inflammatory response via secretory phospholipase A 2 ( sPLA 2 ), a phospholipid hydrolase that releases fatty acids, including precursors of eicosanoids. Methods and Results: Mmp2 −/− (and, to a lesser extent, Mmp7 −/− and Mmp9 −/− ) mice had between 10‐ and 1000‐fold elevated sPLA 2 activity in plasma and heart, increased eicosanoids and inflammatory markers (both in the liver and heart), and exacerbated lipopolysaccharide‐induced fever, all of which were blunted by adenovirus‐mediated MMP ‐2 overexpression and varespladib (pharmacological sPLA 2 inhibitor). Moreover, Mmp2 deficiency caused sPLA 2 ‐mediated dysregulation of cardiac lipid metabolic gene expression. Compared with liver, kidney, and skeletal muscle, the heart was the single major source of the Ca 2+ ‐dependent, ≈20‐ kD a, varespladib‐inhibitable sPLA 2 that circulates when MMP ‐2 is deficient. PLA 2G5, which is a major cardiac sPLA 2 isoform, was proinflammatory when Mmp2 was deficient. Treatment of wild‐type ( Mmp2 +/+ ) mice with doxycycline (to inhibit MMP ‐2) recapitulated the Mmp2 −/− phenotype of increased cardiac sPLA 2 activity, prostaglandin E 2 levels, and inflammatory gene expression. Treatment with either indomethacin (to inhibit cyclooxygenase‐dependent eicosanoid production) or varespladib (which inhibited eicosanoid production) triggered acute hypertension in Mmp2 −/− mice, revealing their reliance on eicosanoids for blood pressure homeostasis. Conclusions: A heart‐centric MMP ‐2/ sPLA 2 axis may modulate blood pressure homeostasis, inflammatory and metabolic gene expression, and the severity of fever. This discovery helps researchers to understand the cardiovascular and systemic effects of MMP ‐2 inhibitors and suggests a disease mechanism for human MMP ‐2 gene deficiency.